Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$11.28 USD
-0.02 (-0.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Enanta Pharmaceuticals, Inc falls in the month of September.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -133.82 | -121.76 | -79.00 | -36.17 | 46.38 |
Depreciation/Amortization & Depletion | -0.48 | 4.14 | 5.45 | 3.95 | -1.08 |
Net Change from Assets/Liabilities | 8.02 | 6.79 | -13.69 | 12.90 | 11.49 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 23.12 | 26.04 | 17.24 | 26.41 | 14.62 |
Net Cash From Operating Activities | -103.15 | -84.78 | -70.00 | 7.09 | 71.42 |
Property & Equipment | -9.06 | -2.13 | -0.75 | -1.45 | -5.42 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -44.52 | 57.02 | 37.74 | 21.27 | -81.25 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -53.58 | 54.90 | 36.99 | 19.83 | -86.66 |
Uses of Funds
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.21 | 21.26 | 3.61 | 10.48 | 6.85 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 195.92 | -1.23 | -0.53 | -1.50 | -4.19 |
Net Cash from Financing Activities | 198.13 | 20.03 | 3.08 | 8.98 | 2.57 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 41.39 | -9.85 | -29.93 | 35.90 | -12.67 |
Cash at Beginning of Period | 47.96 | 57.81 | 87.74 | 51.84 | 64.51 |
Cash at End of Period | 89.36 | 47.96 | 57.81 | 87.74 | 51.84 |
Diluted Net EPS | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 |
Fiscal Year End for Enanta Pharmaceuticals, Inc falls in the month of September.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.22 | -64.56 | -33.41 | -133.82 | -105.71 |
Depreciation/Amortization & Depletion | 1.92 | 1.56 | 0.92 | -0.48 | -1.09 |
Net Change from Assets/Liabilities | -2.03 | -4.73 | -1.38 | 8.02 | 1.82 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 18.97 | 14.14 | 8.89 | 23.12 | 23.43 |
Net Cash From Operating Activities | -68.36 | -53.59 | -24.99 | -103.15 | -81.55 |
Property & Equipment | -9.00 | -2.46 | -0.79 | -9.06 | -7.69 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 48.16 | 47.96 | -12.33 | -44.52 | -57.72 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 39.16 | 45.51 | -13.12 | -53.58 | -65.41 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.08 | 0.05 | 0.00 | 2.21 | 2.21 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -20.49 | -13.82 | -7.35 | 195.92 | 195.94 |
Net Cash from Financing Activities | -20.41 | -13.76 | -7.35 | 198.13 | 198.15 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -49.61 | -21.85 | -45.46 | 41.39 | 51.18 |
Cash at Beginning of Period | 89.36 | 89.36 | 89.36 | 47.96 | 47.96 |
Cash at End of Period | 39.74 | 67.51 | 43.90 | 89.36 | 99.15 |
Diluted Net EPS | -1.07 | -1.47 | -1.58 | -1.34 | -1.86 |